Thelansis

 Alpha-1 Antitrypsin Deficiency (AATD) is an autosomal codominant genetic condition that can result in serious lung disease in adults and/or liver disease at any age. AATD occurs when the blood is deficient in a protein called Alpha-1 antitrypsin, or AAT. The liver mainly produces AAT, which primarily protects the lungs from increased protease activity. The responsible gene, SERPINA1, is located on the long arm of chromosome 14 (14q31–32.3). According to Thelansis disease modeling data and literature review estimated, ~78000 patients with AATD in the United States in the year 2020. Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ...